Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice

[1]  G. Garlet,et al.  Macrophage Polarization and Alveolar Bone Healing Outcome: Despite a Significant M2 Polarizing Effect, VIP and PACAP Treatments Present a Minor Impact in Alveolar Bone Healing in Homeostatic Conditions , 2021, Frontiers in Immunology.

[2]  E. Waller,et al.  643 Vasoactive intestinal peptide as a novel immune checkpoint molecule in activated T cells , 2021, Journal for ImmunoTherapy of Cancer.

[3]  O. Mir,et al.  Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2021, Pharmacology & therapeutics.

[4]  T. Xue,et al.  Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer , 2021, World Journal of Surgical Oncology.

[5]  Xiang Gao,et al.  PD-L1 induces macrophage polarization toward the M2 phenotype via Erk/Akt/mTOR. , 2021, Experimental cell research.

[6]  Christine E. Brown,et al.  Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy , 2021, Frontiers in Immunology.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  Xiangliang Yang,et al.  Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles , 2021, Nature communications.

[9]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[10]  W. Seeger,et al.  Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer , 2020, Science Advances.

[11]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[12]  T. Smyrk,et al.  Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Marimuthu Citartan,et al.  Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice , 2020, Frontiers in Oncology.

[14]  J. Pouysségur,et al.  Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response , 2019, International journal of molecular sciences.

[15]  N. Zhang,et al.  Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy. , 2019, Nanoscale.

[16]  L. Galluzzi,et al.  Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.

[17]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[18]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[19]  A. Nishiyama,et al.  (Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations , 2018, British Journal of Cancer.

[20]  M. Kandefer-Szerszeń,et al.  Colon cancer–derived conditioned medium induces differentiation of THP-1 monocytes into a mixed population of M1/M2 cells , 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[21]  Jun-Long Zhao,et al.  Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression , 2018, Front. Immunol..

[22]  J. Chen,et al.  Establishment of a 12-gene expression signature to predict colon cancer prognosis , 2018, PeerJ.

[23]  C. Flowers,et al.  Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. , 2018, Blood advances.

[24]  E. Waller,et al.  Activation of VIP signaling enhances immunosuppressive effect of MDSCs on CMV-induced adaptive immunity , 2017, Oncotarget.

[25]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[26]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[27]  E. Waller,et al.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia , 2017, Oncoimmunology.

[28]  A. Puig-Kröger,et al.  VIP impairs acquisition of the macrophage proinflammatory polarization profile , 2016, Journal of leukocyte biology.

[29]  B. Blazar,et al.  Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling. , 2016, Cancer research.

[30]  Mei Liu,et al.  Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells , 2016, Oncotarget.

[31]  J. Ge,et al.  Vasoactive intestinal peptide represses activation of tumor-associated macrophages in gastric cancer via regulation of TNFα, IL-6, IL-12 and iNOS. , 2015, International journal of oncology.

[32]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[33]  Xiu‐da Shen,et al.  Vasoactive intestinal peptide attenuates liver ischemia/reperfusion injury in mice via the cyclic adenosine monophosphate–protein kinase a pathway , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  L. Southerland,et al.  Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. , 2013, Blood.

[35]  R. Palmqvist,et al.  The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.

[36]  M. Delgado,et al.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions , 2013, Amino Acids.

[37]  W. Mosgoeller,et al.  Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients , 2010, Peptides.

[38]  C. Martínez,et al.  VIP–PACAP System in Immunity , 2006, Annals of the New York Academy of Sciences.

[39]  I. Gozes,et al.  A VIP hybrid antagonist: From developmental neurobiology to clinical applications , 1995, Cellular and Molecular Neurobiology.

[40]  D. Pozo,et al.  The Significance of Vasoactive Intestinal Peptide in Immunomodulation , 2004, Pharmacological Reviews.

[41]  Y. Ueda,et al.  Vasoactive intestinal peptide and its relationship to tumor stage in colorectal carcinoma: an immunohistochemical study , 2002, Journal of Gastroenterology.

[42]  C. Pan,et al.  A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. , 2002, Diabetes.

[43]  M. Delgado,et al.  Inhibition of IFN-γ-Induced Janus Kinase-1-STAT1 Activation in Macrophages by Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide , 2000, The Journal of Immunology.

[44]  P. de Neef,et al.  Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation. , 1999, European journal of biochemistry.

[45]  M. Goldman,et al.  The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. , 1998, Immunology letters.

[46]  T. Moody,et al.  Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. , 1996, Cancer Research.

[47]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .

[48]  T. Moody,et al.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. , 1991, The Journal of pharmacology and experimental therapeutics.

[49]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.